Oct 2026
Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era
Background/Aim: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy has demonstrated efficacy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure. However, real-world evidence in the osimertinib era remains limited. T...
Y. Taniguchi, Tsunehiro Tanaka, M. Tamiya et al.
· Anticancer Research · 0 citations